Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic–Cardio–Renal Perspective for the Primary Care Physician

被引：0

作者：

Roopa Mehta

Daniel Pichel

Chih Hao Chen-Ku

Pablo Raffaele

Antonio Méndez Durán

Francisco Padilla

Jose Javier Arango Alvarez

José Esteban Costa Gil

Juan Esteban Gómez Mesa

Mariano Giorgi

Rodolfo Lahsen

Andrei C. Sposito

机构：

[1] National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ),Metabolic Diseases Research Unit (UIEM)

[2] Hospital Paitilla,Department of Medicine/Cardiology

[3] Clínica Los Yoses,Department of Nephrology

[4] San Pedro Montes de Oca,Coordinacion de Planeacion de Infraestructura Medica

[5] Fundación Favaloro University Hospital,Internal Medicine/Cardiology

[6] Instituto Mexicano del Seguro Social,Cardiology Section, Cardiovascular Prevention Unit

[7] Cardiología Clínica e Intervencionista,Centro de Diabetes Adultos

[8] Clinica del Café,Department of Cardiology

[9] Instituto de Cardiología y Cirugía Cardiovascular,undefined

[10] Fundación Valle del Lili,undefined

[11] CEMIC,undefined

[12] Clinica Las Condes,undefined

[13] State University of Campinas (Unicamp),undefined

来源：

Diabetes Therapy | 2021年 / 12卷

关键词：

Antidiabetic drugs; Cardiovascular disease; Heart failure; Hypoglycemia; Type 2 diabetes mellitus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Growing scientific evidence from studies on type 2 diabetes (T2D) has recently led to a better understanding of the associated metabolic–cardio–renal risks. The large amount of available information makes it essential to have a practical guide that summarizes the recommendations for the initial management of patients with T2D, integrating different aspects of endocrinology, cardiology, and nephrology. The expert consensus presented here does not attempt to summarize all the evidence in this regard but rather attempts to define practical summary recommendations for the primary care physician to improve the clinical prognosis and management of patients with T2D, while ensuring economic sustainability of health systems, beyond glycemic control.

引用

页码：1 / 20

页数：19

共 242 条

[1]

Chatterjee S(2017)Type 2 diabetes Lancet 389 2239-2251

[2]

Khunti K(2019)Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet 393 3-5

[3]

Davies MJ(1979)Diabetes and cardiovascular disease. The Framingham study JAMA 241 2035-2038

[4]

Verma S(2019)Vascular complications in patients with type 2 diabetes: prevalence and comorbidities in 6 countries of Latin America (a cohort of the discover study program) Endocr Pract 25 994-1002

[5]

Jüni P(2019)Primary care management of patients with type 2 diabetes: overcoming inertia and advancing therapy with the use of injectables Clin Ther 41 352-367

[6]

Mazer CD(2016)Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review Br J Gen Pract 66 e114-e127

[7]

Kannel WB(2011)Type 2 diabetes mellitus: practical approaches for primary care physicians J Am Osteopath Assoc. 111 S3-S12

[8]

Chen-Ku CH(2009)Refill adherence and polypharmacy among patients with type 2 diabetes in general practice Pharmacoepidemiol Drug Saf 18 983-991

[9]

Gonzalez-Galvez G(2007)Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America Rev Panam Salud Pública. 22 12-20

[10]

Vásquez M(2020)Barriers and facilitators to successful management of type 2 diabetes mellitus in Latin America and the Caribbean: a systematic review. PLoS ONE 15 e0237542-861

← 1 2 3 4 5 6 7 8 9 10 →